IgE disruptor for food allergy with Claude-enabled antibody design [pdf]

JumpCrisscross

Entire classes of allergies are basically caused by IgE, our worm-targeting depth charges, getting bored by the lack of worms in our bodies for possibly the first time in millennia. If we could tweak our bodies we wouldn’t want to eliminate IgE. But we’d want to have it produced only when a recognizer complex finds thar be worms.

altairprime

Was this reviewed by anyone outside of their employer? The logo dead center at the top at least gives away that it’s not an academic paper, and without independent review this seems like a fancy press release in LaTeX academic clothing.

ChrisArchitect

Related: Early progress on accelerating drug development with Claude https://news.ycombinator.com/item?id=50265609

areoform

Fun fact. You can't use Claude to analyze this research paper. Because... bioweapons! > Opus 5.5's safeguards flagged this message. You may be seeing this for the first time on an Opus model: Opus 5.5 is more capable and has stronger safeguards as a result, which can sometimes flag biology-research-adjacent work. We're improving these safeguards to reduce the amount of incorrectly flagged messages. Send feedback or learn more. > > Details: [bio] The question asked was, "Can you please compare this receptor design against existing results and show where the difference is? This seems very incremental. It's hard to see the value add." It's very funny, because IIRC, there's interesting prior art here. Doing this with Rosetta has been a thing for a while now, https://docs.rosettacommons.org/docs/latest/application_docu... https://docs.rosettacommons.org/docs/latest/getting_started/... I remember hearing about people who wanted to use it to help make vaccines for Zika because there's antibody dependent enhancement there... Not sure what happened. But the Rosetta project is refreshingly open, https://rosettacommons.org/about/ as entities like OpenAI were meant to be when they first started. There's no gatekeeping here. Do you want to learn how to design an antibody? Here's how you begin, https://www.youtube.com/watch?v=89bQALrPoN0 here's a google colab notebook for it, https://colab.research.google.com/drive/1avuqX7sCjVWX3maOibB... Google Colab let's you just do it... Starting at $10, https://colab.research.google.com/signup you can access really great GPUs for compute and design antibodies (that will almost certainly never work) to your heart's content. Because that's how it should be. Science and mathematics work because the results are shared. And most importantly, null results, tools, and frameworks are shared. If these tools are to be used to accelerate science, then they need to be accessible and shared. Even if it's at a high sticker price (assuming that they're costly). Gating access is a net negative for humanity and our scientific progress. It's also very pointless.

ValleZ

Opus 5.5 blocks any biology research that even remotely looks like this. I guess that the "safeguards" are for peasants only.

hcknwscommenter

The disrupter effect seems quite weak. Their comparator is omalizumab, which is not a potent disrupter itself. Some AI will tell you omalizumab is a disrupter, but it really is a blocker because it blocks binding of IgE to its receptor in the first place. That's quite different. IgE disrupters are known in general. The challenge is not finding an IgE disrupter, but finding one that is "human" enough to work as a chronic treatment. [Edit to add:] https://pmc.ncbi.nlm.nih.gov/articles/PMC8502201/